<SEC-DOCUMENT>0001144204-13-036150.txt : 20130621
<SEC-HEADER>0001144204-13-036150.hdr.sgml : 20130621
<ACCEPTANCE-DATETIME>20130621172036
ACCESSION NUMBER:		0001144204-13-036150
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20130621
DATE AS OF CHANGE:		20130621

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TG THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001001316
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				363898269
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-189015
		FILM NUMBER:		13928011

	BUSINESS ADDRESS:	
		STREET 1:		787 SEVENTH AVENUE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
		BUSINESS PHONE:		(212) 554-4484

	MAIL ADDRESS:	
		STREET 1:		787 SEVENTH AVENUE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MANHATTAN PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20030310

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ATLANTIC TECHNOLOGY VENTURES INC
		DATE OF NAME CHANGE:	20000330

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ATLANTIC PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19960703
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>v348253_424b5.htm
<DESCRIPTION>PROSPECTUS SUPPLEMENT - RULE 424(B)(5)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">FILED PURSUANT TO RULE 424(b)(5)&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>REGISTRATION NO. 333-189015 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROSPECTUS SUPPLEMENT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(to Prospectus dated June 17, 2013) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>$50,000,000 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;<B>&nbsp;</B><IMG SRC="logo1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have entered into an At-the-Market Issuance Sales Agreement,
or sales agreement, with MLV &amp; Co. LLC, or MLV, relating to the sale of shares of our common stock offered by this prospectus
supplement and the accompanying prospectus. In accordance with the terms of the sales agreement, under this prospectus supplement
and accompanying prospectus we may offer and sell shares of our common stock, $0.001 par value per share, having an aggregate offering
price of up to $50.0 million from time to time through MLV, acting as agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common stock is traded on The NASDAQ Capital Market,
or the Exchange, under the symbol &ldquo;TGTX.&rdquo; The last reported sale price of our common stock on June 20, 2013 was
$7.49 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sales of our common stock, if any, under this prospectus supplement
and the accompanying prospectus will be made by any method permitted that is deemed an &ldquo;at-the-market&rdquo; offering as
defined in Rule 415 under the Securities Act of 1933, as amended, or the Securities Act, including sales made directly on or through
the Exchange, the existing trading market for our common stock, sales made to or through a market maker other than on an exchange
or otherwise, in negotiated transactions at market prices, and/or any other method permitted by law. MLV is not required to sell
any specific amount, but will act as our sales agent using commercially reasonable efforts consistent with its normal trading and
sales practices. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">MLV will be entitled to compensation at a commission rate of
up to 3% of the gross sales price per share sold. In connection with the sale of the common stock on our behalf, MLV may be deemed
to be an &ldquo;underwriter&rdquo; within the meaning of the Securities Act and the compensation of MLV may be deemed to be underwriting
commissions or discounts. We have also agreed to provide indemnification and contribution to MLV with respect to certain liabilities,
including liabilities under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investing in these securities involves a high degree of risk.
Before buying shares of our common stock, you should carefully consider the risk factors described in &ldquo;Risk Factors&rdquo;
beginning on page S-4 of this prospectus supplement and in the documents incorporated by reference into this prospectus supplement
and any free writing prospectus that we have authorized for use in connection with this offering. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these securities, or determined if this prospectus supplement and the accompanying
prospectus is accurate or complete. Any representation to the contrary is a criminal offense. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><IMG SRC="logo2.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this Prospectus is June 21,
2013</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Prospectus Supplement </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 93%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: windowtext 1pt solid; text-align: center">Page</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="4">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; padding-bottom: 0; padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">ABOUT
    THIS PROSPECTUS SUPPLEMENT</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">S-3</TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-bottom: 0; padding-left: 12pt; text-indent: -12pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; padding-bottom: 0; padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">FORWARD-LOOKING
    STATEMENTS</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">S-4</TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD COLSPAN="4">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; padding-bottom: 0; padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">PROSPECTUS
    SUPPLEMENT SUMMARY</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">S-5</TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD COLSPAN="4">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; padding-bottom: 0; padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">RISK
    FACTORS</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">S-6</TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD COLSPAN="4">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; padding-bottom: 0; padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">USE
    OF PROCEEDS</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">S-7</TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD COLSPAN="4">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; padding-bottom: 0; padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">DIVIDEND
    POLICY</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">S-7</TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-bottom: 0; padding-left: 12pt; text-indent: -12pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; padding-bottom: 0; padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">DILUTION</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">S-8</TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD COLSPAN="4">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; padding-bottom: 0; padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">PLAN
    OF DISTRIBUTION</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">S-9</TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD COLSPAN="4">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; padding-bottom: 0; padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">LEGAL
    MATTERS</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">S-10</TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD COLSPAN="4">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; padding-bottom: 0; padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">EXPERTS</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">S-10</TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD COLSPAN="4">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; padding-bottom: 0; padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">WHERE
    YOU CAN FIND&nbsp;ADDITIONAL&nbsp;INFORMATION ABOUT US</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">S-11</TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD COLSPAN="4">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; padding-bottom: 0; padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">INCORPORATION
    OF CERTAIN DOCUMENTS BY REFERENCE</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">S-11</TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Prospectus </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 95%; padding-left: 12pt; text-indent: -12pt"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; border-bottom: windowtext 1pt solid; text-align: center">Page</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="text-transform: uppercase">TG Therapeutics, Inc.</FONT></TD>
    <TD STYLE="text-align: center">1</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="text-transform: uppercase">The Offering</FONT></TD>
    <TD STYLE="text-align: center">1</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="text-transform: uppercase">Where You Can Find More Information</FONT></TD>
    <TD STYLE="text-align: center">1</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="text-transform: uppercase">Important Information About This
    Prospectus</FONT></TD>
    <TD STYLE="text-align: center">2</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="text-transform: uppercase">Incorporation of Certain Information
    by Reference</FONT></TD>
    <TD STYLE="text-align: center">2</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="text-transform: uppercase">Description of Securities We May
    Offer</FONT></TD>
    <TD STYLE="text-align: center">3</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="text-transform: uppercase">Description of Common Stock</FONT></TD>
    <TD STYLE="text-align: center">3</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="text-transform: uppercase">Plan of Distribution</FONT></TD>
    <TD STYLE="text-align: center">4</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="text-transform: uppercase">Legal Matters</FONT></TD>
    <TD STYLE="text-align: center">5</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="text-transform: uppercase">Experts</FONT></TD>
    <TD STYLE="text-align: center">5</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You should rely only on the information contained in or incorporated
by reference in this prospectus supplement, the accompanying prospectus and any free writing prospectus that we have authorized
for use in connection with this offering. We have not, and MLV has not, authorized anyone to provide you with different information.
If anyone provides you with different or inconsistent information, you should not rely on it. We are not, and MLV is not, making
an offer to sell these securities in any jurisdiction where the offer or sale is not permitted or in which the person making that
offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make an offer or solicitation. You should
assume that the information appearing in this prospectus supplement, the accompanying prospectus, the documents incorporated by
reference in this prospectus supplement and the accompanying prospectus, and any free writing prospectus that we have authorized
for use in connection with this offering, is accurate only as of the date of those respective documents. Our business, financial
condition, results of operations and prospects may have changed since those dates. You should read this prospectus supplement,
the accompanying prospectus, the documents incorporated by reference in this prospectus supplement and the accompanying prospectus,
and any free writing prospectus that we have authorized for use in connection with this offering, in their entirety before making
an investment decision. You should also read and consider the information in the documents to which we have referred you in the
sections of this prospectus supplement entitled &ldquo;Where You Can Find Additional Information About Us&rdquo; and &ldquo;Incorporation
of Certain Documents by Reference.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This document is in two parts. The first part is this prospectus
supplement, which describes the terms of this offering and also adds to and updates information contained in the accompanying
prospectus and the documents incorporated by reference in this prospectus supplement and the accompanying prospectus. The second
part, the accompanying prospectus dated June 17, 2013, including the documents incorporated by reference therein, provides more
general information, some of which may not apply to this offering. Generally, when we refer to this prospectus, we are referring
to both parts of this document combined. To the extent there is a conflict between the information contained in this prospectus
supplement, on the one hand, and the information contained in the accompanying prospectus or in any document incorporated by reference
that was filed with the Securities and Exchange Commission, or SEC, before the date of this prospectus supplement, on the other
hand, you should rely on the information in this prospectus supplement. If any statement in one of these documents is inconsistent
with a statement in another document having a later datefor example, a document incorporated by reference in the accompanying
prospectusthe statement in the document having the later date modifies or supersedes the earlier statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We further note that the representations, warranties and covenants
made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference into the accompanying
prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating
risk among the parties to such agreement, and should not be deemed to be a representation, warranty or covenant to you. Moreover,
such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties
and covenants should not be relied on as accurately representing the current state of our affairs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unless otherwise indicated in this prospectus or the context
otherwise requires, all references to &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; &ldquo;the Company,&rdquo; and &ldquo;TG&rdquo;
refer to TG Therapeutics, Inc. and its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORWARD-LOOKING STATEMENTS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certain matters discussed in this prospectus supplement and
the accompanying prospectus may constitute forward-looking statements for purposes of the Securities Act of 1933, as amended, or
the Securities Act, and the Securities Exchange Act of 1934, as amended, or the Exchange Act, and involve known and unknown risks,
uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from
the future results, performance or achievements expressed or implied by such forward-looking statements. The words &ldquo;anticipate,&rdquo;
&ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;may,&rdquo; &ldquo;expect&rdquo; and similar expressions are generally intended
to identify forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking
statements due to a variety of factors, including, without limitation, those discussed under the captions &ldquo;Risk Factors,&rdquo;
&ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo; and elsewhere in this
prospectus supplement and the accompanying prospectus, as well as other factors which may be identified from time to time in our
other filings with the Securities and Exchange Commission, or the SEC, or in the documents where such forward-looking statements
appear. All written or oral forward-looking statements attributable to us are expressly qualified in their entirety by these cautionary
statements. Such forward-looking statements include, but are not limited to, statements about our:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>expectations for increases or decreases in expenses;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>expectations for the pre-clinical and clinical development, manufacturing, regulatory approval, and commercialization (including
market acceptance) of TG-1101, TGR-1202 or any other products we may acquire or in-license;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>expectations for incurring capital expenditures to expand our research and development and manufacturing capabilities;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>expectations for generating revenue or becoming profitable on a sustained basis;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>expectations or ability to enter into marketing and other partnership agreements;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>expectations or ability to enter into product acquisition and in-licensing transactions;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>expectations or ability to build our own commercial infrastructure to manufacture, market and sell our drug candidate;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>estimates of the sufficiency of our existing cash and cash equivalents and investments to finance our operating requirements,
including expectations regarding the value and liquidity of our investments;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>expected losses; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>expectations for future capital requirements.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The forward-looking statements contained in this prospectus
supplement and the accompanying prospectus reflect our views and assumptions only as of the date of this prospectus supplement
and the accompanying prospectus, respectively. Except as required by law, we assume no responsibility for updating any forward-looking
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We qualify all of our forward-looking statements by these cautionary
statements. In addition, with respect to all of our forward-looking statements, we claim the protection of the safe harbor for
forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>&nbsp;</B><B>PROSPECTUS SUPPLEMENT SUMMARY </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; border-top: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This summary highlights information
contained elsewhere or incorporated by reference in this prospectus supplement and the accompanying prospectus. This summary does
not contain all of the information that you should consider before deciding to invest in our common stock. You should read this
entire prospectus supplement and the accompanying prospectus carefully, including the &ldquo;Risk Factors&rdquo; section contained
in this prospectus supplement and the accompanying prospectus, our consolidated financial statements and the related notes thereto
and the other documents incorporated by reference in this prospectus supplement and the accompanying prospectus. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Our Company </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a biopharmaceutical company focused
on the acquisition, development and commercialization of innovative and medically important pharmaceutical products for the treatment
of cancer and other underserved therapeutic needs. We aim to acquire rights to these technologies by licensing or otherwise acquiring
an ownership interest, funding their research and development and eventually either out-licensing or bringing the technologies
to market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currently, the Company is developing
two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, third generation monoclonal antibody that
targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. We are also developing TGR-1202, an orally
available PI3K delta inhibitor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also actively evaluate complementary
products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities. To date, we have
not received approval for the sale of any of our drug candidates in any market and, therefore, have not generated any product sales
from our drug candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our principal executive offices are located
at 787 Seventh Avenue, New York, New York 10019, and our telephone number is 212-554-4484. We maintain a website on the Internet
at www.tgtherapeutics.com and our e-mail address is info@tgtxinc.com. Our Internet website, and the information contained on it,
are not to be considered part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The Offering </B></P>
&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-top: Black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 1%; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; width: 37%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-bottom: 0; padding-left: 0; width: 1%">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; width: 60%">&nbsp;</TD>
    <TD STYLE="width: 1%; border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 0; padding-left: 0; padding-right: 0"><FONT STYLE="font-size: 10pt">Common&nbsp;stock&nbsp;offered&nbsp;by&nbsp;us&nbsp;pursuant&nbsp;to this prospectus supplement</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-bottom: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; text-align: justify; padding-bottom: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">Shares of our common stock having an aggregate offering price of up to $50.0 million.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 0; padding-left: 0; padding-right: 0"><FONT STYLE="font-size: 10pt">Manner of offering</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-bottom: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; text-align: justify; padding-bottom: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">&ldquo;At-the-market offering&rdquo; that may be made from time to time on The NASDAQ Capital Market or other market for our common stock in the U.S. through our agent, MLV &amp; Co. LLC. See the section entitled &ldquo;Plan of Distribution&rdquo; on page S-9 of this prospectus supplement.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 0; padding-left: 0; padding-right: 0"><FONT STYLE="font-size: 10pt">Use of proceeds</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-bottom: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; text-align: justify; padding-bottom: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">We intend to use the net proceeds of this offering for the continued development of TG-1101 and TGR-1202, the acquisition, development and commercialization of other pharmaceutical products, and for general corporate purposes. See the section entitled &ldquo;Use of Proceeds&rdquo; on page S-7 of this prospectus supplement.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 0; padding-left: 0; padding-right: 0"><FONT STYLE="font-size: 10pt">Risk factors</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-bottom: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; text-align: justify; padding-bottom: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">See &ldquo;Risk Factors&rdquo; beginning on page&nbsp;S-6 of this prospectus supplement and the other information included in, or incorporated by reference into, this prospectus supplement for a discussion of certain factors you should carefully consider before deciding to invest in shares of our common stock.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 0; padding-left: 0; padding-right: 0"><FONT STYLE="font-size: 10pt">NASDAQ Capital Market symbol</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-bottom: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-bottom: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">TGTX</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 0; padding-left: 0; padding-right: 0; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-bottom: 0; padding-left: 0; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-bottom: 0; padding-left: 0; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B>&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RISK FACTORS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Investment in our common stock involves risks. Before deciding
whether to invest in our common stock, you should consider carefully the risk factors discussed below and those contained in the
section entitled &ldquo;Risk Factors&rdquo; contained in our Annual Report on Form 10-K for the year ended December 31, 2012, as
filed with the SEC on March 21, 2013, which is incorporated herein by reference in its entirety, as well as any amendment or update
to our risk factors reflected in subsequent filings with the SEC. If any of the risks or uncertainties described in our SEC filings
actually occurs, our business, financial condition, results of operations or cash flow could be materially and adversely affected.
This could cause the trading price of our common stock to decline, resulting in a loss of all or part of your investment. The risks
and uncertainties we have described are not the only ones facing our company. Additional risks and uncertainties not presently
known to us or that we currently deem immaterial may also affect our business operations. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Associated with this Offering </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>We have broad discretion in the use of the net proceeds of
this offering and may not use them effectively. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We intend to use the net proceeds from this offering for general
corporate purposes and to continue clinical trials of our product candidates. However, our management will have broad discretion
in the application of the net proceeds from this offering and could spend the proceeds in ways that do not improve our results
of operations or enhance the value of our common stock. The failure by management to apply these funds effectively could result
in financial losses that could have a material adverse effect on our business, cause the price of our common stock to decline and
delay the development of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>You will experience immediate and substantial dilution.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The offering price per share in this offering may exceed the
net tangible book value per share of our common stock outstanding prior to this offering. Assuming that an aggregate of 6,675,567
shares of our common stock are sold at a price of $7.49 per share, the last reported sale price of our common stock on the Exchange
on June 20, 2013, for aggregate gross proceeds of $50.0 million, and after deducting commissions and estimated offering expenses
payable by us, you will experience immediate dilution of $5.52 per share, representing the difference between our as adjusted net
tangible book value per share as of December 31, 2012 after giving effect to this offering and the assumed offering price. The
exercise of outstanding stock options and warrants will result in further dilution of your investment. See the section entitled
&ldquo;Dilution&rdquo; below for a more detailed illustration of the dilution you would incur if you participate in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>You may experience future dilution as a result of future
equity offerings.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In order to raise additional capital, we may in the future offer
additional shares of our common stock or other securities convertible into or exchangeable for our common stock at prices that
may not be the same as the price per share in this offering. We may sell shares or other securities in any other offering at a
price per share that is less than the price per share paid by investors in this offering, and investors purchasing shares or other
securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares
of our common stock, or securities convertible or exchangeable into common stock, in future transactions may be higher or lower
than the price per share paid by investors in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>USE OF PROCEEDS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may issue and sell shares of our common stock having aggregate
sales proceeds of up to $50.0 million from time to time. Because there is no minimum offering amount required as a condition to
close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at
this time. We estimate that the net proceeds from the sale of the shares of common stock that we are offering may be up to approximately
$48.4 million, after deducting MLV&rsquo;s commission and estimated offering expenses payable by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We intend to use the net proceeds of this offering for the continued
development of TG-1101 and TGR-1202, the acquisition, development and commercialization of other pharmaceutical products, and for
general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DIVIDEND POLICY </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have never declared or paid any cash dividends on our common
stock and do not anticipate paying any cash dividends in the foreseeable future. Any future determination to pay dividends will
be at the discretion of our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DILUTION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If you invest in our common stock, your interest will be diluted
to the extent of the difference between the price per share you pay in this offering and the net tangible book value per share
of our common stock immediately after this offering. Our net tangible book value of our common stock as of December 31, 2012 was
approximately $15.6&nbsp;million, or approximately $0.60 per share of common stock based upon 25,820,738 shares outstanding. Net
tangible book value per share is equal to our total tangible assets, less our total liabilities, divided by the total number of
shares outstanding as of December 31, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">After giving effect to the sale of our common stock in the aggregate
amount of $50.0 million at an assumed offering price of $7.49 per share, the last reported sale price of our common stock
on The NASDAQ Capital Market on June 20, 2013, and after deducting estimated offering commissions payable by us, our net tangible
book value as of December 31, 2012 would have been $64.1&nbsp;million, or $1.97 per share of common stock. This represents
an immediate increase in net tangible book value of $1.37 per share to our existing stockholders and an immediate dilution
in net tangible book value of $5.52 per share to new investors in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">The following table illustrates this calculation
on a per share basis:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 91%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Offering price per share</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">7.49</TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Net tangible book value per share</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">0.60</TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Increase in net tangible book value per share attributable to the offering</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">1.37</TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">As-adjusted net tangible book value per share after giving effect to the offering</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">1.97</TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Dilution in net tangible book value per share to new investors</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">5.52</TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The number of shares of our common stock to be outstanding immediately
after this offering is based on 25,820,738 shares of our common stock outstanding as of December 31, 2012. The number of shares
outstanding as of December 31, 2012 excludes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 9%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 0">6,781,007 shares issuable upon exercise of outstanding warrants with a
    weighted average exercise price of $1.58; </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 9%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 0">46,984 shares issuable upon exercise of outstanding options with a
    weighted average exercise price of $61.08;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 9%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 0">862,438 shares issued in connection with warrant exercises and restricted
    stock grants between January 1 and June 20, 2013; and </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 9%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 0">17,403 shares issuable upon  the conversion of certain notes payable at a
    weighted average exercise price of $1,078.04.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The foregoing table does not give effect to the exercise of
any outstanding options or warrants. To the extent options and warrants are exercised, there may be further dilution to new investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PLAN OF DISTRIBUTION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have entered into an At-the-Market Issuance Sales Agreement
with MLV under which we may issue and sell our common stock from time to time through MLV acting as agent, subject to certain limitations,
including the number of shares registered under the registration statement to which the offering relates. The form of the sales
agreement was filed as an exhibit to a report filed under the Securities Exchange Act of 1934, as amended, or the Exchange Act,
and is incorporated by reference in this prospectus supplement. The sales, if any, of shares made under the sales agreement will
be made by any method that is deemed an &ldquo;at-the-market&rdquo; offering as defined in Rule 415 promulgated under the Securities
Act, including sales made directly on or through the Exchange, the existing trading market for our common stock, sales made to
or through a market maker other than on an exchange or otherwise, in negotiated transactions at market prices, and/or any other
method permitted by law. We may instruct MLV not to sell common stock if the sales cannot be effected at or above the price designated
by us from time to time. We or MLV may suspend the offering of common stock upon notice and subject to other conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each time we wish to issue and sell common stock under the sales
agreement, we will notify MLV of the number of shares to be issued, the dates on which such sales are anticipated to be made, any
minimum price below which sales may not be made and other sales parameters as we deem appropriate. Once we have so instructed MLV,
unless MLV declines to accept the terms of the notice, MLV has agreed to use its commercially reasonable efforts consistent with
its normal trading and sales practices to sell such shares up to the amount specified on such terms. The obligations of MLV under
the sales agreement to sell our common stock is subject to a number of conditions that we must meet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will pay MLV commissions for its services in acting as agent
in the sale of common stock. MLV will be entitled to a commission of up to 3% of the gross proceeds from the sale of common stock
offered hereby. In addition, we have agreed to reimburse certain expenses of MLV in an amount not to exceed $25,000. We estimate
that the total expenses for the offering, excluding compensation payable to MLV under the terms of the sales agreement, will be
approximately $75,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Settlement for sales of common stock will generally occur on
the third business day following the date on which any sales are made, or on some other date that is agreed upon by us and MLV
in connection with a particular transaction, in return for payment of the net proceeds to us. There is no arrangement for funds
to be received in an escrow, trust or similar arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the sale of the common stock on our behalf,
MLV may, and will with respect to sales effected in an &ldquo;at-the-market offering,&rdquo; be deemed to be an &ldquo;underwriter&rdquo;
within the meaning of the Securities Act and the compensation of MLV may be deemed to be underwriting commissions or discounts.
We have agreed to provide indemnification and contribution to MLV against certain civil liabilities, including liabilities under
the Securities Act. We have also agreed to reimburse MLV for certain other specified expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The offering of our common stock pursuant to the sales agreement
will terminate upon the earlier of (i) the sale of all of our common stock provided for in this prospectus supplement or (ii) termination
of the sales agreement as provided therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">MLV and its affiliates may in the future provide various investment
banking and other financial services for us and our affiliates, for which services they may in the future receive customary fees.
To the extent required by Regulation M, MLV will not engage in any market making activities involving our common stock while the
offering is ongoing under this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LEGAL MATTERS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The validity of the common stock offered hereby will be passed
upon by Alston &amp; Bird LLP, New York, New York. LeClairRyan, A Professional Corporation, New York, New York, is counsel for
MLV in connection with this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXPERTS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The consolidated financial statements of TG Therapeutics, Inc.
and subsidiaries as of December 31, 2012 and 2011 and for the years then ended, and the cumulative period ended December 31, 2012,
have been incorporated by reference herein in reliance upon the report of CohnReznick LLP, independent registered public accounting
firm, and upon the authority of said firm as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WHERE YOU CAN FIND&nbsp;ADDITIONAL&nbsp;INFORMATION
ABOUT US </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We file reports with the SEC on an annual basis using Form 10-K,
quarterly reports on Form 10-Q and current reports on Form 8-K. You may read and copy any such reports and amendments thereto at
the SECs Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549 on official business days during the hours of 10:00
a.m. to 3:00 p.m. Please call the SEC at 1-800-SEC-0330 for information on the Public Reference Room. Additionally, the SEC maintains
a website that contains annual, quarterly, and current reports, proxy statements, and other information that issuers (including
us) file electronically with the SEC. The SECs website address is http://www.sec.gov. You can also obtain copies of materials we
file with the SEC from our Internet website found at www.tgtherapeutics.com. Our stock is quoted on the NASDAQ Capital Market under
the symbol &ldquo;TGTX.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus supplement and the accompanying prospectus are
only part of a registration statement on Form S-3 that we have filed with the SEC under the Securities Act and therefore omits
certain information contained in the registration statement. We have also filed exhibits and schedules with the registration statement
that are excluded from this prospectus supplement, and you should refer to the applicable exhibit or schedule for a complete description
of any statement referring to any contract or other document. You may inspect a copy of the registration statement, including the
exhibits and schedules, without charge, at the public reference room or obtain a copy from the SEC upon payment of the fees prescribed
by the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INCORPORATION OF CERTAIN DOCUMENTS BY
REFERENCE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The SEC allows us to &ldquo;incorporate by reference&rdquo;
the information we file with them which means that we can disclose important information to you by referring you to those documents
instead of having to repeat the information in this prospectus supplement and accompanying prospectus. The information incorporated
by reference is considered to be part of this prospectus supplement and accompanying prospectus, and later information that we
file with the SEC will automatically update and supersede this information. We incorporate by reference the documents listed below
and any future filings made with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act between the date of this
prospectus supplement and the termination of the offering (other than, unless otherwise specifically indicated, current reports
furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed on such form that are related to such items):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 9%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%">&bull;</TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 0"><FONT STYLE="font-size: 10pt">Our Annual Report on Form 10-K for the year ended December 31, 2012; </FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 0">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&bull;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 0"><FONT STYLE="font-size: 10pt">Our Quarterly Report on Form 10-Q for the quarter ended March 31, 2013;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 9%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%">&bull;</TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 0"><FONT STYLE="font-size: 10pt">Our Current Reports on Form 8-K filed with the SEC on May 14, 2013, May 28, 2013, June 3, 2013 and June 6, 2013;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 9%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%">&bull;</TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 0"><FONT STYLE="font-size: 10pt">Our Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 24, 2013; and</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 0">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&bull;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 0"><FONT STYLE="font-size: 10pt">The description of our common stock contained in our registration statement on Form 8-A filed with the SEC on May 28, 2013 (File No. 001-32639).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We also incorporate by reference all documents we file under
Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act until all of the common stock to which this prospectus supplement and the
accompanying prospectus relates has been sold or the offering is otherwise terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 18pt"><B>$175,000,000<BR>
</B></FONT></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TG Therapeutics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">We may offer and sell an indeterminate number
of shares of our common stock from time to time under this prospectus. You should read this prospectus and any prospectus supplement
carefully before you invest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">We may offer our common stock in one or more
offerings in amounts, at prices, and on terms determined at the time of the offering. We may sell our common stock through agents
we select or through underwriters and dealers we select. If we use agents, underwriters or dealers, we will name them and describe
their compensation in a prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">This prospectus provides a general description
of the securities we may offer. Each time we sell securities, we will provide specific terms of the securities offered in a supplement
to this prospectus. The prospectus supplement may also add, update or change information contained in this prospectus. You should
read this prospectus and the applicable prospectus supplement carefully before you invest in any securities. This prospectus may
not be used to consummate a sale of securities unless accompanied by the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Our common stock is traded on the NASDAQ
Capital Market under the symbol &ldquo;TGTX.&rdquo; On May 30, 2013, the per share closing price of our common stock as reported
on the NASDAQ Capital Market was $6.25 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><B>Investing in our securities involves certain
risks. See &ldquo;Risk Factors&rdquo; in our Annual Report on Form 10-K for the year ended December 31, 2012, as well as our Quarterly
Report on Form 10-Q for the period ended March 31, 2013, which has been filed with the SEC and is incorporated by reference into
this prospectus. You should read the entire prospectus carefully before you make your investment decision.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful
or complete. Any representation to the contrary is a criminal offense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is June 17,
2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Table of Contents</U> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 95%; padding-left: 12pt; text-indent: -12pt">&nbsp;</TD>
    <TD STYLE="width: 5%; border-bottom: windowtext 1pt solid; text-align: center">Page</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">TG Therapeutics, Inc.</TD>
    <TD STYLE="text-align: center">1</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">The Offering</TD>
    <TD STYLE="text-align: center">1</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Where You Can Find More Information</TD>
    <TD STYLE="text-align: center">1</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Important Information About This Prospectus</TD>
    <TD STYLE="text-align: center">2</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Incorporation of Certain Information by Reference</TD>
    <TD STYLE="text-align: center">2</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Description of Securities We May Offer</TD>
    <TD STYLE="text-align: center">3</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Description of Common Stock</TD>
    <TD STYLE="text-align: center">3</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Plan of Distribution</TD>
    <TD STYLE="text-align: center">4</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Legal Matters</TD>
    <TD STYLE="text-align: center">5</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Experts</TD>
    <TD STYLE="text-align: center">5</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TG THERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are a biopharmaceutical company focused
on the acquisition, development and commercialization of innovative and medically important pharmaceutical products for the treatment
of cancer and other underserved therapeutic needs. We aim to acquire rights to these technologies by licensing or otherwise acquiring
an ownership interest, funding their research and development and eventually either out-licensing or bringing the technologies
to market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Currently, the Company is developing two
therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, third generation monoclonal antibody that targets
a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. We are also developing TGR-1202, an orally available
PI3K delta inhibitor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We also actively evaluate complementary
products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities. To date, we have
not received approval for the sale of any of our drug candidates in any market and, therefore, have not generated any product sales
from our drug candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Our principal executive offices are located
at 787 Seventh Avenue, New York, New York 10019, and our telephone number is 212-554-4484. We maintain a website on the Internet
at www.tgtherapeutics.com and our e-mail address is info@tgtxinc.com. Our Internet website, and the information contained on it,
are not to be considered part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 53%; padding-top: 0; padding-bottom: 0; padding-left: 0.5in">Use of Proceeds</TD>
    <TD STYLE="width: 47%; padding-top: 0; padding-bottom: 0">We intend to use the net proceeds of any offering as set forth in the applicable prospectus supplement. </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-top: 0; padding-bottom: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0; padding-bottom: 0; padding-left: 0.5in">Nasdaq Symbol</TD>
    <TD STYLE="padding-top: 0; padding-bottom: 0">TGTX</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-indent: -3in"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: center; text-indent: -3.5in"><B>WHERE
YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: center; text-indent: -3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">We file reports with the SEC on an annual
basis using Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. You may read and copy any such reports and
amendments thereto at the SEC&rsquo;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549 on official business
days during the hours of 10:00 a.m. to 3:00 p.m. Please call the SEC at 1-800-SEC-0330 for information on the Public Reference
Room. Additionally, the SEC maintains a website that contains annual, quarterly, and current reports, proxy statements, and other
information that issuers (including us) file electronically with the SEC. The SEC&rsquo;s website address is http://www.sec.gov.
You can also obtain copies of materials we file with the SEC from our Internet website found at www.tgtherapeutics.com. Our stock
is quoted on the NASDAQ Capital Market under the symbol &ldquo;TGTX.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>IMPORTANT INFORMATION ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">This prospectus is part of a &ldquo;shelf&rdquo;
registration statement that we filed with the SEC. By using a shelf registration statement, we may sell our securities, as described
in this prospectus, from time to time in one or more offerings. We may use the shelf registration statement to offer and sell securities
described in this prospectus. Each time we sell securities, we will provide a prospectus supplement to this prospectus that contains
specific information about the terms of such offering. The supplement may also add, update or change information contained in this
prospectus. Before purchasing any securities, you should carefully read both this prospectus and any supplement, together with
the additional information incorporated into this prospectus or described under the heading &ldquo;Where You Can Find More Information.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">You should rely only on the information contained
or incorporated by reference in this prospectus and any prospectus supplement. We have not authorized any other person to provide
you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We
will not make an offer to sell securities in any jurisdiction where the offer or sale is not permitted. You should assume that
the information appearing in this prospectus, as well as information we previously filed with the SEC and have incorporated by
reference, is accurate as of the date on the front cover of this prospectus only, or when such document was filed with the SEC.
Our business, financial condition, results of operations and prospects may have changed since the relevant date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">We will not use this prospectus to offer
and sell securities unless it is accompanied by a prospectus supplement that more fully describes the terms of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INCORPORATION OF CERTAIN INFORMATION
BY REFERENCE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The SEC allows us to &ldquo;incorporate by
reference&rdquo; into this prospectus the information we file with the SEC. This means that we can disclose important information
to you by referring you to those documents without restating that information in this document. The information incorporated by
reference into this prospectus is considered to be part of this prospectus, and information we file with the SEC pursuant to Section
13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, after the date of this prospectus
and prior to the termination of this offering, will automatically update and supersede the information contained in this prospectus
and documents listed below. We incorporate by reference into this prospectus the documents listed below, except to the extent information
in those documents differs from information contained in this prospectus, and any future filings made by us with the SEC under
Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, including exhibits:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD>Our Annual Report on Form 10-K for the year ended December 31, 2012;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD>Our Quarterly Report on Form 10-Q for the quarter ended March 31, 2013;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD>Our Current Reports on Form 8-K filed with the SEC on May 14, 2013 and May 28, 2013;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD>Our Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 24, 2013 and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD>The description of our common stock contained in our registration statement on Form 8-A filed with the SEC on May 28, 2013
(File No. 001-32639).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">We will provide to each person, including
any beneficial owner, to whom a copy of this prospectus is delivered, a copy of any or all of the information that we have incorporated
by reference into this prospectus. We will provide this information upon written or oral request at no cost to the requester. You
may request this information by contacting our corporate headquarters at the following address: 787 Seventh Avenue, New York, New
York 10019, Attn: Chief Financial Officer, or by calling (212) 554-4484.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DESCRIPTION OF COMMON STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The following summary of the terms of our
common stock may not be complete and is subject to, and qualified in its entirety by reference to, the terms and provisions of
our amended and restated certificate of incorporation and our restated bylaws. You should refer to, and read this summary together
with, our amended and restated certificate of incorporation and restated bylaws to review all of the terms of our common stock
that may be important to you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Under our certificate of incorporation, we
are authorized to issue a total of 500,000,000 shares of common stock, par value $0.001 per share. As of December 31, 2012 we had
issued and outstanding 25,820,738 shares of our common stock. There are approximately 234 holders of record. All outstanding shares
of our common stock are fully paid and nonassessable. Our common stock is listed on the NASDAQ Capital Market under the symbol
&ldquo;TGTX.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Dividends</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Subject to the dividend rights of the holders
of any outstanding series of preferred stock, holders of our common stock are entitled to receive ratably such dividends and other
distributions of cash or any other right or property as may be declared by our board of directors out of our assets or funds legally
available for such dividends or distributions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Voting Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The holders of our common stock are entitled
to one vote for each share of common stock owned by that stockholder on every matter properly submitted to the stockholders for
their vote. Stockholders are not entitled to vote cumulatively for the election of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Liquidation and Dissolution</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In the event of any voluntary or involuntary
liquidation, dissolution or winding up of our affairs, holders of common stock would be entitled to share ratably in our assets
that are legally available for distribution to stockholders after payment of liabilities. If we have any preferred stock outstanding
at such time, holders of the preferred stock may be entitled to distributions and/or liquidation preferences. In either such case,
we must pay the applicable distribution to the holders of our preferred stock (if any) before we may pay distributions to the holders
of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Other</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Holders of our common stock have no conversion,
redemption, preemptive, subscription or similar rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Transfer Agent</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">American Stock Transfer and Trust Company
serves as the transfer agent and registrar for all of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">We may sell the securities covered in this
prospectus in any of three ways (or in any combination):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>through underwriters or dealers;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>directly to a limited number of purchasers or to a single purchaser; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>through agents.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Each time that we use this prospectus to
sell securities, we will also provide a prospectus supplement that contains the specific terms of the offering. The prospectus
supplement will set forth the terms of the offering of the securities, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the name or names of any underwriters, dealers or agents and the amounts of any securities underwritten or purchased by each
of them; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the public offering price of the common stock and the proceeds to us and any discounts, commissions or concessions allowed
or reallowed or paid to dealers.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Any public offering price and any discounts
or concessions allowed or reallowed or paid to dealers may be changed from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">If underwriters are used in the sale of any
securities, the securities will be acquired by the underwriters for their own account and may be resold from time to time in one
or more transactions, including negotiated transactions, at a fixed public offering price or at varying prices determined at the
time of sale. The securities may be either offered to the public through underwriting syndicates represented by managing underwriters,
or directly by underwriters. Generally, the underwriters&rsquo; obligations to purchase the securities will be subject to certain
conditions precedent. The underwriters will be obligated to purchase all of the securities if they purchase any of securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">We may sell the securities through agents
from time to time. The prospectus supplement will name any agent involved in the offer or sale of the securities and any commissions
we pay to them. Generally, any agent will be acting on a best efforts basis for the period of its appointment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">We may authorize underwriters, dealers or
agents to solicit offers by certain purchasers to purchase the securities from us at the public offering price set forth in the
prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future.
The contracts will be subject only to those conditions set forth in the prospectus supplement, and the prospectus supplement will
set forth any commissions we pay for solicitation of these contracts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Agents and underwriters may be entitled to
indemnification by us against certain civil liabilities, including liabilities under the Securities Act of 1933, as amended, or
to contribution with respect to payments which the agents or underwriters may be required to make in respect thereof. Agents and
underwriters may be customers of, engage in transactions with, or perform services for us in the ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">We may enter into derivative transactions
with third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If
the applicable prospectus supplement indicates, in connection with those derivatives, the third parties may sell securities covered
by this prospectus and the applicable prospectus supplement, including in short sale transactions. If so, the third party may use
securities pledged by us or borrowed from us or others to settle those sales or to close out any related open borrowings of securities,
and may use securities received from us in settlement of those derivatives to close out any related open borrowings of securities.
The third party in such sale transactions will be an underwriter and will be identified in the applicable prospectus supplement
(or a post-effective amendment).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In compliance with the guidelines of the
Financial Services Regulatory Authority, Inc., or FINRA, the maximum compensation to be received by a FINRA member or independent
broker-dealer may not exceed 8% of the offering proceeds. It is anticipated that the maximum compensation to be received in any
particular offering of securities will be less than this amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LEGAL MATTERS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The legality and validity of the securities
offered from time to time under this prospectus will be passed upon by Alston &amp; Bird LLP, New York, New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXPERTS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The consolidated financial statements of
TG Therapeutics, Inc. and Subsidiaries as of December 31, 2012 and 2011, and for the years then ended, and the cumulative period
ended December 31, 2012, have been incorporated by reference herein and in the registration statement in reliance upon the report
of CohnReznick LLP, independent registered public accounting firm, and upon the authority of said firm as experts in accounting
and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;&nbsp;</B></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 0.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>$50,000,000</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;<IMG SRC="logo1.jpg" ALT=""></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TG Therapeutics, Inc.</B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<HR ALIGN="CENTER" NOSHADE SIZE="1" STYLE="color: Black; width: 20%; margin-top: 0pt; margin-bottom: 0pt">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PROSPECTUS
SUPPLEMENT </B></P>
<HR ALIGN="CENTER" NOSHADE SIZE="1" STYLE="color: Black; width: 20%; margin-top: 0pt; margin-bottom: 0pt">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><IMG SRC="logo2.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>June 21, 2013</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 0.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo1.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0(!`0$!
M`0(!`0$"`@("`@("`@(#`P0#`P,#`P("`P0#`P0$!`0$`@,%!00$!00$!`3_
MVP!#`0$!`0$!`0(!`0($`P(#!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$
M!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`3_P``1"`!=`3X#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^_BD(!QGU
MI:8_0#U.!4S<5'WM@]2*62)"=S`,",@]^*\[U_XM?#3PMJ=GHGB/QQX;T?5]
M0=8[33+[4HH;R5FQM'ED[ESG^("OG[]L[XB^+?AY\-],N/".I?V/>^(M?&@W
M.J11^;?6$9MYY2]N#P'/ED9)&,C%?B[/OU"2:ZOYI;VZO%47\^HSRW\U]LX!
MF)<)(2<G=(C$9`Z"OX_\=/I10\*N*5PCEF7QQ&+A&,YRF^6*C*/,HINRYFM5
MKLGU/,QF8RPLG3E"Y_2Y:ZC97<5O<VES!=6UU&)K:X@E$L4Z%0P>-APZX8'<
MI(YZUI`A@"#D'H:_$_\`8_\`B?XVT'XI^$_`4&OW5SX-\2ZA<0:AH=]_IEK;
MR+:R,DMIN.8#F'E8R$P?N>G[61G:@4\E``<?Y]Z_8_!CQ=RKQCX2?$^74G3Y
M9<DXMWM)1BW\O>ZZ_([,-7IUZ,9TU;N2T4@.<^QQ2U^OFX4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%,<\J#T).?;BGU')T'NW/Y&IDKQ:_,$KNQ\0_MU^%O$OBCX9Z
M`GAG0-4U^32?%<>IW\&D6QO;FWB-O/$S^2OS/CS#PO/'Y_C:\CP2&)XVB,&W
M[5$[8F@W_=5\X*-G/#+Q7],4X7=]T%G&$XP6*YX)]!G]37Y[_M*ZW^ROH.NV
M6J^+?#>G^+_B':DSQZ!X<N!8W5_M/`U,AA$$!/6;#?45_"7TH/`?`<2XK$<?
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M:R5I-;6N8X&OAL)%T(MZN]W\C]C?-;S%3"X;&3W[_P"%6*\O\`_%#P1\2],B
MUCP;XALM:@""2XAAFV7VG9&=MQ"PW(P!^ZP!Y[BO1EF#*IRZY&1N&#^5?Z"Y
M;FV`S/!T\=E]:%6A.R52$E*+?;1[GM1<9P4XNZ9:HJMR@)=PN.K'M2"9&)'F
MJ<<\<&O5L)RBG:Y:HJOO3_GHOX&FF11_RU.!Z=*0.<([LM45$'W=,_A_^JHU
MGC>1XQ/&S`9,:_?09ZG]!0)5(OT+-%0%P,#<136E7IYF/T--JP>T7R+-%5RZ
M8_UWY'FG1.K$A7+X'(/:D634444`%%%%`!1110`4449`ZG%`!129'J/SI:!7
M3V"BBB@84444`%%%%`!132ZK]Y@.,\TX'(R.AY%`!12'../6C!]3^E!+DD["
MT4@[\YP:6@:=U<*CE!*C!QSS4E-;H/K_`$-3)R46X[E)V=SXE_;<\=>*?`GP
M]T)O"VKSZ)<>(?$B:-?WUB/*U`VXMY[ADAGS^Z)\H@MSU[5\7_`']D/5OBKI
M=IXKU_6!X>\#7LD@M_L(2ZU_Q%Y+O`[`D".+F(YED#,2>F.:^I?^"A:L_P`.
M_`:C`)\=B,`]LZ?>@?S_`$KUO]D`^;^SS\.YEX5[>^D`/#`-?73#(]<'FOXD
MS_@;*/$SZ3.+R#C#FK8'"86G6A2YVH2FW!>\KZJS>UMSSYQ57'NE4UBHW_+_
M`#/5O`'PF\$_"_1?[&\&:#;Z7;.P:[N!F2_U!ATDN9V^=F_'OZ5Y;\8?V6_A
MW\6%EU`VC>&/%GE,(O%&A0113SOSAKNW(\J9><X?+<#!%?494L'`QR1UZ=:A
M8$+(N,GIA1Z@5_4>8<#<(9GP]_JWC<NHRP#CRJGR1M%;7B[73\[W.N5&A*/+
MRJQ^!?CKP+\4_P!ECQY9W-OKMO9:V]E+J'AC7-$N)&M]?AA+*R36I^15#/@K
M<;@"_P`O!%?N-X#U6[UKPAX5UB]9)KO5?#MGJ5S-&GE)*\T"2$JO8$MFOS)_
MX*'97QK\-`00?^$2U.3Z#[7;C_V<?D:_27X5@K\./AZIZKX&TM#CIQ90#^E?
MS5]'SA_"\&>+'%O`F1SG'*\-[*5*E*3E&G*HDW)<U]==/(Y,+%4<36A':*37
MS-'Q_K6J^&?`?C;Q+H&C2>(M<\/^$=2U[0]`B5Y)==O+.SFN+6S14!<F:6..
M(!`6)<8!-?SNZM_P6`_X*!>&_#EYXK\2_P#!-?6/#>A:5I;ZWKFJZT_BRTTS
M1;6*+SIKFYE?30D2*!(26/`3J:_I/D7S(U3`.,8#`%6.01U!].N.*^.O^"A$
M4B?L,_M:EY90!^S]XI?,<K%U_P")5/NY;(8CG!.!["O[//2H1I1DHN*=S\6/
M`/\`P6U_;1^*UA<:M\+?V#M/^(FCV.J'1-1UGP5J_B;Q)I>F7@B$WV2>6"P9
M4E\LJ^PD$*RGH1G]F/@G^U//JO[*NA_M)_M3>'+#]F:Z73+[5/''AKQ9<W6E
M0^#TM-1GM($D%VD4YDN5AC>)"F^3S`%5L@5^7G_!NW([?LX_'\ER"G[0*0_*
MI7*IX5T4`=<#)RQ(`Y;IWKF?^#BGQOK^B_"C]GOP/8W$L'A_Q;X^UWQAXDA1
M,PZH?#=C8/90S@8W!3>RR`<MF)<%2,BHI-V9VRPM"KBEAU&R5G^'_!-3QM_P
M6V^('Q)\6Z]X4_8:_9$\;?'BP\/Z@MIJ7CO7(-2G@NC(@>)TTC3H0T$+#&W[
M?=P7&6'^BUG6/_!:7]H;X/7-K/\`MH?L*^-_ACX(-Q]FU3Q[X5BUK31I$;<R
M.UCJUJ+><)&LKF,7N6V8`[U][?!S4/`_[`7_``3.\.?$C1?"A\0:5\._@39_
M&'Q7I.A7D.D:GXZU+4;6SU#49VO9-T;7,[7J#S)1M8Q(%\M>GYJ:W_P<-_!+
MQMX>U7P[XE_8^U[Q;H&J:?<0:GX?U;XE^']>T75H5CE$L$D4UJ8V#!&!5ESA
MAQ3]FW\)K"E*JI4:.'4DNMW?\S^E'PQKECXI\/Z)XCTHO+I?B/2K?7M+EE5H
MI7MKV&.YMV9&)*DQRH2O.#D#@5\&?ME?M#_MI?!CQEX2T;]F7]D`?M'>&-9\
M.2:IXF\2'Q;+X>;P[?+=&!+/RT0[R80)>#T/48KZX^`GC/2/B3\'/A7X^\.Z
M`/"N@>,?A[H_B71/#6])/[`M+NPMIK>RW(H0^3&4C^7Y?DX.,8]?:,EB=S,"
M<[2Y"BI:L[,\VE>A4;J1O_=>R^X_G`O?^"M_[?EA\9M,_9UO_P#@G[X;A^-V
MKZ!_PE6E_#P_$.^CUB]T\Q7$OGQMY6P?);7#'G.(FK[#^"'[8_[>_B?Q'XO?
M]H']A.#X&?#WPI\*/$'CN#QU<>-I]7CGU32+,W=II<L7EY6.Y"3!G'($9QSP
M?F+Q^@/_``<+_"7('F']GB(JWWC&!HOBG=ANH)(';GFOV\^.\17X'?&#[TG_
M`!:KQ(0K-A"?[%OA@_7)_*E;2YW8R5*FJ<(4TG.*;>NEVO,^6/\`@F[^V3K_
M`.V[^SDOQJ\4^"]"^'FKGQ]J_@Y?#/AK6+CQ!8B+2H[$^<LTT<;LS&Z.0JD`
M!>^:_0".\MFPHGC+`?-\X.PYQAB.`<\8)K^0#_@E9^S'^UC^U=^S?<Z)X:_:
MM\=_LN_LZ>!?'VH6FEVWPFMY+7QO\0/$-W::;>:G-=W<-U`Z6EHILUCPY)DE
M?Y>6Q]M_LT?$[]JK]D#_`(*)>'?V"/CM\=M>_:*^'WQ@\$GQW\./'GCV[N+W
MQ9HN$U::T+3RRRSD23Z!J5M-:F0JS0[@Z+C<TF]C&MAU3JSIQ?PL_H>6:V;8
M`I+/]Q?+.]N2"0,9P"#D]!QZBGI<6X9PC1ET;RW575F0]=I`YS[=:_G&N/B/
M^TS_`,%-/VG?CAX#^%'[2NN?LC?LH_L^^)6\!:MXA\&7B6'Q`^)FK)+=6LDR
MS1S0,PF:TNU4F8PV\5C&3'*[$#(^)7B3]JK_`()4>/\`X1^/[O\`:V\9?M@_
MLM>/O&MG\/?'WA/XL:P?$'C_`,$M>R!!/:WHN;@XAB!E62+R8RP*/&H/F&O9
MSO:Q$</.4G'R/Z46N(FY(D.$WGRP6``SR?R/Y5&]W;1D"0;&89"R,%<C.TL1
MUQDC)Z#UK^=7_@H=\:OVO#_P4Q_9I^!'[+'QJU/P3_PMCX"V#:9HVIW;W_PY
MM+C4]4\=VESXEOM-7)EFMK&TMYD=!O)MH@=NWC]#_@1^R_\`M-_LZ_`7X_\`
MAZW_`&K-=_:.^.7Q#AOO$OPP\=_%NQO(-'\%ZL-!BL+*W-BU[>YM%O(S.\,6
MU3G.T$\-0TU"K16'IPG6>L]4EV/TB-Q"D89&5H]H964Y5@>A4CKG(`QU)Q4?
MVR*0-Y3Q2>7+Y3F*42!&!`*,1P&^9?E//S"OYNOB+^SYX@\-+?7GQL_X+I>+
M_!W[0<1DN8].T;XA6?@WX:^&M1<"/[%)HJ7^^.%)65?,F2.1`0QC8+L/U5_P
M2;_:P^+'[17PD^/7@_XQ>)]#\?>.OV>_%O\`PAEK\7-"G0KXYTRXCOVL+W>L
M2EGBDL+EDG"_OD>%V(;<%.1&<J$I1LC]EUNU8N%96,6/-"R@F+=R-WID<\T1
MW2`N6(4[B"&)4D@@=#R>6`^IQUK^2/\`8(N_^"B/_!0#2/'?PYN/VQ_B3\-_
M@WX`\:W=_P"//BQ#<SZA\6-:O+ZT$=GX9T>_6>&2UMH8(Q=2;)0H\UB`Q;%?
M3VL>-_VP/^"6'[0GP,T'XN_M'>+_`-JK]E'X[>++?P3=^(?B2\C^,_`-Q-);
MVIN!)-+.^Z#[7:RF&*=8)HM^(XI%9B<B[FJRZ<*ZI1G>Z?Y7/Z1A<KN8?+M!
MPC9X?H>OT.:4W,:E!(1$)#MC,AV>8>RKGJ>"<#GBOQ=_X*4?M8?'?P]\7_@3
M^P_^RMKFE>`_C;^T%%_;FM_$_5[B$Q_#CP['-?0O<Q(X=1(1INI3M+C<L5HR
MQDNRD?*7QQ_9^_;*_8A^&>L?M-_"3_@I'\2/CQK/PSL8_%7Q+^%/Q@UTZ_X/
M\8VHN(H-3:T@DO;A55,LWE"/>L:GRSOVH9DK,(86I*G&<FKO_.Q_28UQ"')5
M2\BC;C&&X&\8!Z\'/'3ZU(EQ$R*Q8`LN[;G<W;ICKU'(K\$OV]_VQ?'/C'_@
MDW\/_P!J;X*>*?%?P>\2?$;6_"E]%J'A+5GTO7M!:XN[ZVU73XKA5'RB:VGA
M.%&5`'/6ON;XV^._'6A?\$R?'?Q*TCQ5K>F_$+2_V.7\867C.TO0GB&WU6/P
MPMX;Y;@J?WK2C>S;>N<>TF+IRC+E?H?>^I:K;V&FZCJ$X<PZ;82:C<+!'Y]R
MJ11F4[8^I;"Y"G!)Q7S)^R?^UW\(?VS/A[KGQ0^"J^*9_"V@>-[OX?WT_BO0
M&\/WYU&SM[*>X*1%W)B$=]#E\X^0\#%?FY^S]X#^/_[9G_!,7]FSQ2O[7?QD
M^%?CZ!/%/BGQS\0=(F77?$_Q,M;37/$.GKI6JR-+%F!H[>%<C)`C'RYKX5_X
M(X?LN?&+XJ_":;XK>"?VQ/BS\'O"'@G]HJ2'Q!\'?"E@LWA#QX=.CT74;J6]
ME:Y5U:]AN3#*`A!V@9(`--*[L7[*/).5_A_S2/V]M?VBOVA[C]N6_P#V=3^S
MA?C]G.V\,+K%E^TO]IOGL+J^&A6NJ?8U)B-LQ%W*UJ,RY^3[O3/W@)H`@8N%
M`RN>-H(;:1D?+D'@@'@YK\4M,^,WQ<F_X+@^*_@;-\2?&<GP9A_9UA\0Q?"\
MZT[^"(M0&DZ?.+R*Q(VQR[WE8LI^9G&>G/G'[17QV_:F_;&_;>\:?L)?LB_%
M0_L^^!_@[I,-Y\?_`(\:3:3W/B]+G98W%U9Z>T3I*%A%^EG%&DUNSSF[/GQ)
M%$TEJ$6B_872:[79^^YEME(#`*3@8;"D;N!GCC)..:59+=R0JY8`,5"_.`>A
M*XSVK\9_A=^P?^W+^SQ\7/AGXU\)?\%#_B#\;OA?%XQLA\:/AG\=;*]U)]:T
M:28+J?\`8<S7-W'!<$2,\:E8Y"4"_:&)VM\5_%#XU_$;]J?_`(*"?'W]F?XG
M?MQ>,_V'OAA\']2_X1KP'X2\`^(XOA]X@^))RX%V^K3,@,MUA+E3+(4:.91&
M,E@#D70B.&C5G:,M#^G%9H4!7E,9.-AYP,D#CK@$XZ\59!R,CH>17Y2?LS?L
ME_M1?`+XS^'O$/\`PVSXS_:2_9IU7P[?VVK>!OB_'%K/C#3]0:.`:1?:3KB>
M:TT,<F?-S+&,2.5C<YS^K$8(C0'.0HZG)J)*SL9S@J<G!.]@W'&1CW/84QI.
M.<=<9/`YXJ&XE$4#2,0JQC>Q(RH`ZD^WOV[\5\1_&3]M/P-X$^U:+X,@7Q_X
MHA4I+]CO(X_#6E2CHES>J6WN&'^K@#9P<LM?#\8<>\+<#98LTXHQL:%%KW5)
M7G/RC%:MD3G&E!U*FB1SW_!0EY?^%:^#[B**25=/\:K/,Z(3!!C3[P+YTF,1
MJ6>,;FP/FK._9+_:`^%VB?#WP_\`#;6]?7P[K?AY;F*(^("ME9:E')-)+')'
M<@E.0XZ_@*^8-#_;"^(TNM:@_P`2+72O'?@[7!LUOPA=Z3;Z=:VT3#;BWW`A
M2HYQ*9`^`<@G`WM6_9^^&'QLTVYU_P#9N\46%C?0*#JGPR\39@>%PN?]&)'G
MAE``"G,1S]X5_#"\1L5Q!XGXGQ8\'*D,5B94O85<!B$Z-:I3BTU.E=^^[Q24
M4T[.^J1Y"Q,*]=XO!OFTLU]W^1^PMOJ4-W$ES9S6\]O.`\%Q!(+B&=.[@@XQ
M]":Y[Q/XS\,^$['^U?$WB/1O#]HH,R2ZC?);)*%&&P&(9^#_``"OQ*\+?%/X
MU_LYZA>>%MVI:7Y:2PR>%/&-D^JZ;"6_U=Q;1;]J[!D[K=MC8VE><B'0O!'Q
MO_::\0RZU*;[Q)(S^5-XM\4DV'ASP^AD5F6R!4HH(S^ZMB2N,,V37Z%_Q-Q5
MS/`TL@X:X<Q%?B23Y*F%<'%T)7M>3:7-%;W27;S=U,U2@H0I_O+VL=E^U]\7
M?"?QC\;>&IO`_P#:>J67AO1KO19-1-L([;5YKNZMWB6Q3)DFP(V)`4$#'%?K
MS\,(IX/A]X$M[N(P7=OX-TV&YB9&C:)ULXE=2K<C#`C!Y&.:\(^"_P"R9\/O
MA5);^(KW_BK?&D,?[K6]1M_]&TLD$'[);\F/.YQYA)<@]<``?5JJ$3<25(`4
MX;>5`Z<D=Z_1O!;P[XWX?S[./$'CNK3_`+1S)1_<4_L.*]U-]TO^"=N'I5%.
M6(K*SFEIY=OZ^\LJ,E![_P`O_P!5?&__``44F6']A;]K=G:-5'[/?BDYDD$2
MG.ESC;D]SG`]Z^S@B@A@!GJ#5#5=+L=8LKC3M2LK34=/O;=[2^T^_MUN["^A
MD4I)%-"P*2(P)!1P0<]*_I9;:G5!\LE(_GE_X-U)[:X_9O\`VAGMKFVN8X_V
MA%+/:SBX51_PBVB9;<!SR6``]*^P?^"N?[&GBS]L']FZ*+X;6$>I?%7X3:\_
MCKP5H$TBVTGC&)K.>WU+1X)F.(YYXI<QL_R&2*,,"!BOT]\.>"?"OA&&:T\*
M^&/#GA:RN9A=7-GX:T.VT*UN90GEB22.!$5F"`+N8$X`'85TC6L3XWJ&PP?D
M9.0P8?D133:V-UB)*K[9?$?RX?L=?\%<-`_9F^&>A?LJ?MZ?"WXF>%-4^'VF
M1>%=`\3WW@U;]=6T:'Y+.RUG1;AHY5-M&%@6YMA<P3*B$-D$U\W?\%1OVW?V
M:OVW/#'PK^#O[)WA+QEXA\9:!XYN/$.K2:?\+$\.R:U%+IEY80V,4$:?;I&>
M:ZAV>7$R;B,C@$?UU>,/AGX"^(=E'IWQ!\"^#/'FGPL7ALO&OABR\5VD1))R
ML=U'(HZGH.,UG^"_@Y\+?ALLB_#GX9?#OX?++GS1X&\%:;X1\S)!(8VD,>02
MJY!X..<TU.4=F'M[3Y];OS9YY^R-HNJ^&?V8OV>O#^NZ;>:-KFB_!CPWI6L:
M/J-NUIJ&EW$6EVB203QLJLLD9&UE(!!'05])'@$^E5K>V2!`H15"GY0O"J..
M@_#-6:3;;NSG;N[H_G8\?7UH?^#ASX/0_:K<W,G[.:.ML)U6?']B^*,DIG(/
M(XZ\YZ5^X'Q^9F^!'QE&]8E;X2^)=\N0HA']B7_S9)'0D?YY'>R>#?!\WB.#
MQA-X6\-R^++:V^R0>)Y="MI?$D$01XQ&E^8_/"A9'7:'QB1AW-;US:V][;R6
M=Q!#/:SQM#<6\R>;!<1L"KQR(>&5@Q!5L@@D$&C4<\1[7EYGK%)+T1^'7_!O
MC)!=?\$_%EMY()(C\<_$[*UM.MQ'RFDR8$BDY`XZ8X`!%<%^U3<PV_\`P7D_
M8*@:2-&'P'D=5>1(R#))\2H\JN02"%(QT!<$#).?WL\-^$O"_@[3%T7PGX;\
M/^%M'6=[E-)\-Z-;Z%IBR/C?(+>%%3<VT9;&3@9Z56O/!OAB_P#$%GXKO/#7
MAV\\3Z7;FSTOQ+=Z-;7/B'3(2928K>]9#-$F9YCM1@/WK_WC0JBIN[-(UI^T
M=23U>Y_(+\./V;?V.OA9^U1^T?\`"/\`X*8>%/$/@2#Q!\1M0\9_`;XN:SXC
MU?P=\.O$6DWE]?7"V,=W:D6[O*ET9@9F#KAT8#=7UQ-^SG_P05A\0>%O#'@S
MQ#_PLKQCXW\4Z?X;\.^&?A=\1/$7C_6;NZO+N*VMWEBMG:*""*1D9I9F5$`)
M.1D'^C?Q1X`\(>.-)&A>-O"?A?QGHC2^?+HOBW0;7Q+I+28;YS:W*/$&^9OF
M"YYK!\$_!3X3?#2267X;_"WX:_#J6<%9YO`O@+2O"DLZD@E7:U@C)!('!]*M
M8B4_>BS;ZU)2YD]3\/?VDS967_!>W]A'3DFABC@_9T:T@M!*%G$:P_%B-5^\
M&&)'AQU!VKCTK[0_X*Y^(/C!X9_8.^+^H_!`^(H_$E\]AIOB:\\'B8>)-,\-
MSSK#K<]F8MTJ-]GQ"SQ88+(2"#@U^C<W@SPG=Z]8^*+SPWX?O?%.F6AL--\3
MW6C6\_B+38?WV8;>^9#/&G^D7'RHX'[^3CYCG;DM0P96R5;/!).X?*,-SR,*
MN0<@]P<FIO+J85,5S5J<I:QAH?S._`2W_P""%?P:_9^\!>(O$=S\$/B]X_UO
MPC!J>O6'BC1_^%I?%_Q3K,UK;S7^F6&B[6Q<><[PB&!%SD!G9=Q/9?\`!#?4
M-&U"7_@HG>^%])N/#WAVY^*-E)X8\.7EHNF3^&;)HO$T]KITED)'^SM!%+"K
M0'F+=M]*_>'1/@3\&?"OB.Z\9>&?A)\*]!\8W\_GWWBW1OAWH^C^*+R3(;?+
M?P6Z3.V0#N9LY`.:TG\)>&_#.G^*CX6\->&]!OO$,-WJ&KOH6C6^CR:W=RPR
M@W-XT,0,\S-)C?)N9BYYYY.:1T^W4Z,E+R_-'\MO_!&#]M?X1_LY>&OB]\.?
MCUK`^'/@;Q_\4IO$O@[XM:WI\D/@#^TH[.TTR_T"_P!2V&."[V)97$8D8`K=
M+T#<^Y?\%#/CGX,_X*/_`!;_`&8OV8/V1M1_X7);>%?BY;>.OBG\3/!UA-J/
M@/P!:+)!;*\^J!/+1H(I;FZE1L*RF$+(Q&*^AO\`@BY^S[XB\/?LL?''X?\`
M[1WP5N]/M]<_:8U'Q59^#OB]X+AGM-9@/A_PY;KJ$.FWD1BV^9:2*D@CRRPJ
M2Q/3]K/!GP\\%?#W37T7P'X+\'>`M%>8W#:-X*\.V?A;32Y/WC!:QQQDX`R2
M.>]+F>]Q5JT(5^>DK.Q_./\`\%??@+X?M_VR/V=_VD?C/\+O&WQ,_9'N_`4?
MPM^-MQX+ANY;[P7%;W&KB"^NY+;_`$B&';K,-W'@,)FT6X3*>:M5-3^!?_!O
MEHV@1>(3\4O#>H@POJ]GIGACXO>(=3\1ZC*8-QM[;2K9FGEG<11J+5X\[^"-
MU?TTR:=#+%/#/;V\\%Q&T5S#-"LT5RCEBR2*V0RDNQ*MD?,>*\HT3]GOX#^&
M=='BGPY\#O@[X?\`$RS_`&H>(M$^&.B:5KHER6\S[7%;++NR2=V[.2>:-68_
M7?9)4TVDC\@_V^/V>-"UO_@D1I_P\_91\">*;CP?X*7PQ\2O!/@2YANM3\:#
M1I=1^UW1GMYB;EIXHM5GN7B):3;;L,DBO'?C!_P4I_9V\8?\$L;SX:^$?$S>
M)/C;XV_9LD^%FH?![2[>:\\9>!I+;3IM$UK5=<A$8^PV-FEG=70GN"N]&API
MR:_HX2U3>7.-P(==SLVPC`^49PHPH&%P/O<<G/GUM\(/A;::AXDU>S^&7P[M
M-6\96K6/C#5+3P5IEOJ'BN!U"O!J4RPA[J-EX,<Y92.H-#OU,_K2D[GY\?\`
M!)B.34O^"7G[/UG:I"\VH>$O%5G`BOD,\_BCQ&L2JQ`&6:6(C(Q@_C7P%_P1
MM_:%^$W[-7P_^*_[+G[0/CC2/A!\<I/VB;M])\"?$".?1-<US^T[;3='L_L4
M90+.);C3P%,1(*S`[CU']&>B>'="\-Z9:Z)X9T?2O#^CV89;'1]$L8])TNR#
MR/,XBMX@L:!GDD8A0,ESGK7*>(O@Y\+/&'B'2O%WB[X9?#OQ3XLT*6.?0_%'
MB3P1IFO^(M&>(@Q/:7L\+S0LA4%3&RD$9'/-+K<T56-I16SW_,_#K1[F%_\`
M@X9\70"XA^T_\,MQ^;:*R-,2="TTJCKNRAZD9ZCVYKSWP]XYA_X)R?\`!47]
MJKQQ^T#8ZWX;_9W_`&M;FV\0^$/CM<Z/<7OP^T&],D6IK;ZAJ$0?R%6=K[39
M`X'EM;V\A5HWS7]%*>"_#,?B"3Q;'X<T!?%DUF-/F\5#1[=?$TUNH`$#Z@%^
MT-&`H&PN1@8QBIM:\)Z#XDL+K2O$>A:+X@TF](:]TG7--AU;2KQEQM>6VE5H
MG88&&92W`YI\S*C7<59;6L?#]E_P4K_8X\5^.OAY\,?AK\9-)^+WCKXH^)K/
MPIHF@_"6PN/&DMC]JD`.HZE-$HBM+*W19'GGE=2BQLP7(`KY0_:)^)W_``24
M_:-\?>.OA;^UU%X#\&_&'X9:]>>")I/BCIEY\+?'S_97V+=:+K<(3[?82Q^6
M86CFECV`J8\%L_K-X/\`@W\+?AS)?-\.OAG\.?`"ZH6;53X*\$Z;X3;4BQRW
MVAK6&,R9."=Q.>^:?XV^$7PR^)EK;Z?\1_AS\.O']C:[?LMEXW\%:=XOM;?8
MVY!''=PR*@4G(VC@]*+LS4H)W2/Y@?V5;BS^"7_!1SP!\+?^";/Q4\:?M`?L
MI>*5M)/CEX<EU";7OA+\.HFN)!?3PZCLCL_M%C!`;R"XB"-OQ;&.22=7']8<
M#-Y,88`$(`<_)S@9XKBO"'PY\$_#_3(]!\#>#/!_@C089!/%HG@OPW:>%M&5
MP20_V6VCCC+`DL"5.#@C!YKNHT6-0J@!1]T*,`#VI!6J0J)*"L^I\@_MIW-U
M:_`;7GM[RYL))-8LK>2:S?R9WB>;;(A]F5BI]FK\3X(EB`1`B+'F,0JG$*+M
M6)0W?&V0'W%?M-^V\QE^`^M[0V$\0:>6D8?NT'VA022,\#N:_%Y`22_"K.IN
M8"Q`$Z-)(P9#_$/WBC(X!XSZ_P"5/TU'.IXC48*_(J%)1>J7,KW2OI=(^>S9
M24HKR_5C\#_]9S71^#+W4+#QSX)OM/O;FTNH?$UA:_:;6;[/.D4U_:`JK=_N
MM^5<WNZ9P"SB-06`+$GL2<''<=>1Q6]X25I/%_@U$60R/XRTM8XQ&QGFVWRL
MWEQXW/C;T0$\CBOY.X35>IQ3E]'"W==UH<MKWNI)M^EKGEX;W:JOH?O[XV^&
M7@7XD6%GIWCCPQH_B2UM;F.[LHM4TZ*<VCH=V48\\$#BNTL='L=-M;:PT^UM
M[*RME$<%K:VZ6\$2@8`"J/3^57E`/E8'_?56]IR.F`/2O]YL!E.7T\4LVPU)
M1Q4H04JEOB2BC[)I+9#!&I]<C@X.*>%`&,9^O)-*._3KVI:]^"22:5B0HHHJ
M@"BBB@"/RE[9X[$\4;/;]?\`ZU/89!%1[&]OSII"<(RU8]1@$>_UIU-4$#GU
MIU(:22L@P/04444`%1F-22<MR<\&I**`(_*7U;_OJCRE]6_[ZJ2B@"+RP#Q^
MIYI3'[?3)_\`K4K*2<C'3%-V-[?G3LB73A)W9*0#U`/UJ*2,.`!@$'/2I:*1
M15^SYD$C-N(7;D\GK5G`]!^5+10`4F!Z#\J6B@!,#T'Y4N!Z444`-*J01C&?
M3@TWRP.F??+5)3&4G&.U-;A92T8FSV_7_P"M1Y2^K>^&XI-C>WYU(.`!Z"AJ
MPE",=AGE+ZM_WU1Y2#IN'XU)12&-50HP,\G/)S3J**`,:_TNPU.SGM=0LX+Z
MUF0K-:W<"7,$B_-P48$'[Q[5^?/Q?_85\-:PMWKGPCGT_P`):G,/.D\.7AE7
MPO<,"=QCC7+0,<D`1X0D\CI7Z.[1C&,CWI#'&1@HI&,8(R,>F*_/>.?#+A#Q
M%RYY?Q9A(UFDU&I:TX^::,J]&GB(\M5'X*>"_P!E[XL^,?&5[X,NM)'A)]&E
M$6N:[?QQWVE:>),,I@!=7EE:,J1Y?`W#)ZX_5+X0_LP_#3X16\=WI&E)K/B=
MX56Z\6:XHU/57*D,!`7RL*!LD)'C&>I-?2WV>`%F$4:LQW,Z*$<G`&=PYS@`
M?A4@10,``#T%?FGA;]&G@;PTE4QBC]:QCDW"I52O"-[J"WV[[Z'/0P&'H2YX
MZOS&",`@\#!X&*EHP./;I17]&15HI-'8M-`HHHIC"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
'"BBB@#__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo2.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"``7`&@#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#];?\`@NY_
MP3<G\3?#7P#\2_V-_$WQ2^#7QQT\?%>.3P7\*/B1\3_#_A_XR:9X"^"'Q"^-
MB^&KCPIX>\1/IX\;_P!G_"G6M$\#WNBZ+::AKFN^)K+1?$-^VF)97FCY7_!K
MG_P41U3]I7]FOQO^R;\5_&FM>*OC'^S9?)XD\':YXLU>36-?\:_`;QYJ-S<Z
M5+)JNIWUUX@UN_\`AQXQ?5O#&LW.HJR:5X<UWX;64%[<&>2UL/WY^/1_XO3^
MQ&?^K@?'Y_\`-2/VE*_A/_:\\.:Y_P`$#/\`@N?X7_:'^'VBZG9?LU_%'7=4
M^*^EZ%I<9@TG5?@;\5-3DTC]H/X1:?;V$$5E/+\,/$]Q<>)/!/AWR99=%MK3
MX13W45P_V>YN_P#0[Z/,L/\`2*\%?$;Z,>=TL#BO$/*,CQ/BIX#9SB,-E\,Y
MQ6?<+5<SK\2<!RS>=*GF&,I9_DN(Q#RO"XO%UZ.%E2Q$Z:I4L)0IKXO.W+)<
MTP&?TI3C@:E6.79Q24ZCHPHXETXX?&JDFZ<'1JJ*JSC&+E&2<G)L_P!!/XK_
M`!%TKX2_#KQ;\0]6M;G4X_#>E&33/#^G/'_;?C#Q-?3PZ5X/\!>&+:7YM2\8
M^/\`Q7J&B^"_!NB6RS7^O^*==T?1=.MKG4+^UMY?\_'X!Z=\5?VH/^#C?Q3^
MS9^TW\<?C-XP\$W/[2'[14_Q$\&^%OC#\2O!O@S6)?A/\+O''C'1O`VCZ5X:
M\2:-'IGPZTKQ!X9T30K73+:&VNM4\$Z1'I6J3R76I7]Z_P#<9+XKT']H[XW?
M#_1/!^LZ;XG^#_P@\/>%?CYX@\1Z#>6VH:/XN\?^.]*GE^`>@0ZBJ75AJ?A[
M3/"%[KWQFU*'3GBU*+6F^!>NPZI;Z)=7^F>(?XL/V*?^5M'XFG_JYW]NO_U2
MGQ=S_.O-^AO@Z6!X+^F#BJ^!PKSK*/HQ<7YQE^*Q>`PU;'Y)CX8W!4L)B<OK
M8FC5KY=CH4JM2O[?#2H5TJM!\RE2@UIQ+*4L5PVHSFJ=3/L-3G&%2<85H.,G
M*-10:C4A=1CRRO&\7O=G]U#_`+.OP2F\!I\,Y/ASH#>`TU5M<C\.8O19KK3V
M4NEG4DD%V+M;PV,KVWV@7/F;79@0^'K_`#SOVN?A)J/@7_@OU;_L(>#OCA^T
MMX;_`&<?&/[5?[+/@_\`X1/2_P!HGXPB\T#P3\=-`^$GBCQEX5T+6KGQ?/J-
ME86=UXT\0:;X<F:XGOM'T:33K:*\DN+%+D_Z3GL`,`_EC!Z>_MTZ]:_SQOVY
M?^5K_P`!]_\`C,G_`()Y^W_-._V>?Y=*[OV?&+KU^+?I"T\4Z>.IX/Z+?B[Q
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MI**75M61_`6?!NL?\$U/^"\?PZ_9W_:X^*WQV^(O[(US\7+*^\%-\4OC3\4)
M_#.M?!_XWZ=XE\-?!+QIXSN=2\16.B^)](^%GQ$OK#1?B!K$MNOAN]USX;>*
M;F_MK6&VN["V_P!#2'X:^!;;P'/\,+?PQIT/@"ZTS4=%F\+1)*FF-I>J27,F
MH66%F6=([R2[N7<K.KJ\I*,AQC^8G_@ZM_83A^-W[)OA/]L?P=HL-Q\0/V5]
M0DTGXA36MN?[1UO]G[Q_?6]AK1ED@@EN+P_#SQO+H'BJTCGDAL])\-ZK\0]2
M\T2R>7-]3_\`!-+_`(*0^+OVP/\`@E+\+->TC7AJ'[8,OB"P_8KU>5WFN;ZW
M^-JVZ6.E_%_5"]OON=-T[X*[?VE?&$@@$<D'AWQGX=TA]4UG3H;>[_O#Z0<'
MXW^`7@7](G(88?#YOPXH^!GB_@,MH4<!A,OXNR15\VX7XQKX3"*E0P]3BO(\
M3B,3F6:.E&$\9AZ-"I5]I%4X_)9/+^RLYS;):\I2A7OF^63J2=2<\+5Y:6)P
ML93O*7U:O%*%-/2%3W4]62?L3?\`!*KX)7'[3/[6/[3WB#QA\8/B#\'+OX]>
M*/!/[+?P2\2_&WXO:[\*OA_I'P[BL/"WQ3\3GP_J'B[[#XC>[^.&F?$GPWX&
MT35QKWA?PCX-\-:1>:()+S5K>'PU]^^+]7UB/_@JM^S]H*:OJT>@WG[`7[6V
MKWF@1ZG?)H5WJ^G?M"?L9V>GZM=Z.LZZ;<ZKI]GJFIV=AJ4]J]]9VFI:C:VT
M\<%]=)+]K_#GP%X;^%GP_P#`WPS\'6DEAX3^'?A#PYX'\,6<L@EEMO#_`(5T
M>ST/2(9I52-9ITL+"W$TWEH990\A12Y%?#'C,X_X*U?L['T_X)Y?MA'\OVC/
MV):_DS$<6YUQKGN89AGN/K9D\%P;F>5Y<\1&E&-#+\HX=>7X"U&E"-*.)EA\
M)2K8S%*+Q&,QLJV-Q56MBJ]6M+Z)8>GAJ5.%*"ASXFE.=FVW.=93EJVWRJ4F
MHQORQC:,4HI(_&/]OGP5X6^//[1OQ(^/OA#Q]^RWX^\$^)OB_P#"/]C'X4?M
MB_$KXY_'/X<^+O\`@FM^U%X$N5M_%GACX.:1X-\"Z]X!\9:AK/B/6+#Q-IOB
M71O&O@;1];^,]WJWP=^-GB)O#/AVRL8BOK)O^"9W[==E\#?$7_!.W1?CK^R>
M?^"=7B3Q+XOTZ3Q7JOPI^)MS^V7I7P3\<?$W5_BEK?P_@O(/&B?!C4?B#;RZ
MS>^"+#XQ76B6^HFSD3XAR^%QXVA1&*_IS@_Q$X$R+)J63YOXO87*<)EU3ZGP
MY##>%>5>)E3%\.X>C0I9=C,P7$N&IT>%<TJ1C...R3)J=/#5*L/KV-CB,SQ&
M)S',/`QF"Q=:M[2EELJDIKFK.685,"HUI23G&#H-O$4TVG"K4;:ORQM",:<.
M#_:U_P""H/Q$D_:V_8]O?@;^RU\2/BC^SS\%/'WCOQE\??&$GB7X*>$_$FHW
M'BOX6^,/A7H5I\+]!\5_%72-2U"X\'V'CSQ!XHU^+Q%'X9L]>DCTG1M*U"-O
MM=_#J?\`!9_]F#P[_P`%:/\`@FA=?%?X&>'[ZX^,7P(U?4?BI\%[/Q7/I'A?
M4M6BTX6^D_%;X=:A>W&KW7A^QB\6>$%GN],GN]4BTY_&/AGPB;S5M-TO[?=@
MHKP,PQ,/!ROX'>(WASA:/#7&7!V:95/#YUA:N.JULYK5<?BLUJU\^HXG&5L-
MBIU8X_$Y36IX*CE^'KY)*.75Z-2$(S713C_:D<UP..;KX7%4IJ5*2BHTXJ%*
MG:DTE**5E43DY-5??33;O]B?LR^%OAW_`,$AOV%?V?O@M\1[CQ1XY\7Z-X-C
M/CC6_"P/B74_&GQ-T[P]I)\21V&I^+=;T0?V%HMM%I/@+X<P:K>Z9I^B>`?#
M'A/P[;0:)H^C6ME9_P`B'[,MM^U5\*_^"U=[_P`%,O'G[)GC&V^$_BGX^_M!
M>/?$'A#1_B=\`]1\8^&O`/QN\+_$#P9IES%&?BO!IVK:_P"#].\5Z/K>N:?;
MW:0:LVF:OI^DW"2W5C-117WOT<>-<?2R+QPSW,<ORK/LU\<,DXBX2XVQ>;1S
M)265\08O$8[-)Y/#*\RRRG@,97Q4X5H5ZL,7'#NA1A0I4Z:J0J<6=X:'M<JH
MPE.E3RJM1Q.$C3Y-*E&FHTU4YX3YX**LXKEO=W;TM_=$W[9_P<'P<B^.#+XN
M7P9-XGD\(1PG0[<ZVVMQ:1/K30&Q&IM;"$VD$BK<&_\`*\\*A8(?,K^'CXK>
M"_VB?V@O^"[7@W_@H/\`\,]>*O`WP!C_`&L_V9/'/VG7O'7P8O\`Q)IWPM^"
MME\+O"-YXJU/0?#WQ(U6^?4=7TSP->^*_P#A'=,35=1LH=1@T6)[^]MBTA17
MC_1BSB?AK+QDS/(L#@<9CN)>#>+/"K%5\W6,Q#P?#'$4*+S.>`IX/&8"E#-*
MCP6%=/%XN&,I4O9)1PUIU5/7/J4<?_9E*LY1A0QF%Q\%3M&]>A*+I\[E&3<%
MSRO&/+>^KT1_9QXK_P""DW[/GAG0-0UN/3?B3XCDLHV:'0]"\-Z-%J^J3_,L
M%C82>(?%'A_18[FYE"P0R:EK.G6:22(US=6\`DE3^=3X4?%7]N[]NS_@OA^Q
M?^T;\4_@+JWP>_9<^`L_[07AOX.^#M6^(OPB\2:EX.\.^,OV</BMI.M>+O%5
MOX/\>Z[=7WCSXD^(8?":^(;;0+74M*T'3-'\-Z%!?ZG;:!>^)M4**^;\,\OR
M/@G@#Q6X@P?#^4YOGN:\`<8\+87-L^AC,9B>'L#G60XG!YEC.'Z6&QN!P6%S
M;$8.O7P:Q^+PN/G1PU>O2HQIQKUO:=..G5Q.,P%&5:I3I4\9AZ\H47&"K2I5
M8RA&LW&4I4U)*3A&4$VDW>RM_8#X^\#>%/BAX&\9?#;Q[HEGXD\#_$'PMX@\
M$^,?#NH!VL==\+>*=)N]#U_2+Q8V20VVI:7?7=G-Y<BR".8LCHX!7^6O_@WN
M_P""7?C7]C3]HO\`X*%:K\3/$UWKND?!?XZZ=^SY\(=,@URUO-&U>[TGP'%X
M]?XR:YHMJIMX/&NK?!?XT?#WP]I%ZHL+O2+/Q)\1]"O[28W-NNG%%?B?!7B7
MQ=POX9>+OA_E&8*EPOX@X/A.7$6`JT_;*I6R#B+#8K`8G!RE*V$Q+C6KX3$U
M:<6\1@JTZ%3X:4Z?IXC`X;$8W+L95A?$8-XCV,T[65:ERSC)+XHZ*44](R2:
MZI_U@G/\Q].>#SZ#MW-?!/BSP?XFNO\`@IY\"/'L&DO)X-T?]A7]JCPCJ>N?
M;=,5+7Q)XC^/7[(>KZ+I1T][Y-8F:^TSPQKUT+RVTZ?3K8:>8;R]M[FZLH;D
MHK\WR?$U,+7QLJ:BW5R;.,/)33:Y*^`K4IM<KB^91FW%MN*DDW%VL=E5<R2>
MRJTY*UMU4I-:[VU?WL_F=_;,^+/_``51T7QE\/?!7[5?Q(^+7PMU#Q;\8_B'
MH'[+6I_!?Q-X`\&+\</VF]5O]'T3P_\`LBK?_`KXV^"+70OV'M9TZXT/QIX=
M^+?[17@C4OVH=+TC2/%NA:KXH\'^)M3T]]<***_O;)^/:7#_`(<^'F:X3@3P
M^JU.),%G];$X2MD.*HX'!5,IX@QF51>7TLNS3`58?78X=8W'+%UL9S8VK6GA
M?JF'DL-'X[$X65;'8NG+%XR*H.BE*-6+E/VE*%1^T<Z<T^5ODCRJ'N*TN9^\
#?__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
